AI reads Reddit reports on gray market retatrutide and finds hunger near the top

People are already buying gray market retatrutide, a weight loss drug that has not finished its trials and is approved nowhere. A team at the University of Pennsylvania used a large language model to read what those buyers say about it online, and the symptom that came up most often was increased appetite, which is the opposite of what the drug is meant to do. The cross sectional analysis was published in JAMA Network Open. It is a description of what people wrote, not a measurement of what the drug does.

How the study turned Reddit posts into symptom codes

The researchers collected roughly 150,000 Reddit posts and comments from communities devoted to retatrutide and from broader peptide and weight management forums, covering material through December 2025. A language model, checked against human labelling before use, first sorted authors into those who described taking the drug themselves and those who did not. That step identified 13,589 users reporting current use. The same system then pulled out symptoms that each author attributed to the drug and translated the wording into standard medical terms from the MedDRA dictionary, so that a post about a racing heart and a post about palpitations would land in the same bucket. After excluding the expected effects of weight loss and reduced hunger, 7,823 users had at least one coded symptom.

The method matters because the population it reaches is invisible to the usual safety systems. Adverse event reporting runs through clinicians, pharmacies and trial sites, and none of those see a person who ordered a vial of something labelled as an unapproved compound and injected it at home. The same Pennsylvania group had already applied this approach to more than 400,000 Reddit posts about semaglutide and tirzepatide, where reports of menstrual changes appeared more often than the trial record suggested. A separate team later found a similar signal in the regulator's own adverse event database, which is the pattern the authors hope to repeat here.

What the reports actually said

Appetite increase was the most frequently coded symptom among users whose reports could be mapped, followed by fatigue, increased energy, nausea, food craving, insomnia and raised heart rate. That ordering is strange on its face. In the published phase 2 trials of this drug the common complaints were gastrointestinal, led by nausea, and appetite suppression was the point of the treatment rather than a complaint. Compared with the group's earlier reading of semaglutide and tirzepatide discussions, the retatrutide material carried proportionally more talk of appetite changes, sleep problems, faster heart rate and muscle symptoms, and proportionally less about nausea and digestion.

The researchers collected roughly 150,000 Reddit posts and comments from communities devoted to retatrutide and from broader peptide and weight management forums, covering material through December 2025.

Two readings fit these numbers equally well. Retatrutide works on three receptors rather than one or two, so a different pattern of effects is biologically plausible, and the glucagon arm in particular changes energy use. The other reading is that the people writing are different, take other substances alongside, and may not have taken retatrutide at all. The authors do not choose between these, and neither should a reader. Nothing in the dataset records what dose anyone used, how long they continued or what else they were taking, so the comparison with trial data is between two populations as much as between two drugs. The symptom counts also cover only those users whose words could be mapped to a coded term, which leaves out anyone whose report was vague.

Why this is not a list of side effects

The central problem is that nobody knows what was in the vials. Material sold as gray market retatrutide is manufactured outside medical supply chains and is often labelled as not for human use, and analyses of such products have found contents that do not match the label. A symptom that follows an injection of an unidentified powder cannot be attributed to a named molecule. Self reports add a second layer of uncertainty, since people choose what to post, forums amplify whatever is being discussed that week, and nobody records the people who felt nothing at all and said nothing. Posts about gray market retatrutide are a self selected sample of a self selected group.

Then there is the question of who writes. Users willing to source an unapproved drug online differ from trial participants in ways that affect every symptom on the list, including other peptides taken at the same time, stimulants, sleep habits and expectations. Appetite increase, the headline finding, is also what people report when a drug is wearing off or when a product is weak or fake. The authors describe their findings as hypothesis generating and say explicitly that they cannot show that the drug caused anything. One co author discloses an investigator initiated grant from a maker of competing weight loss drugs and consulting fees from a pharmaceutical company.

What AI based pharmacovigilance can and cannot add

The useful claim in this paper is methodological. Reading 150,000 posts by hand is not practical, and a model that sorts self described users from onlookers and maps loose language onto coded terms turns an unreadable pile into counts that someone can check elsewhere. The value lies in that last step. A signal found in forum text is worth something only when another group looks for it in a different dataset, with different biases, and either finds it or does not. The earlier menstrual symptom work followed exactly that path, from forum reports to a database analysis that did not establish cause either.

The limits sit in the same place. Counts of posts cannot give a rate, because the denominator is unknown. Coding by model introduces its own errors, which the authors tried to bound by validating against human labels. And a safety signal about an unapproved product is not a safety signal about the drug a regulator will eventually assess, since the licensed version, if it comes, will be a known quantity made under supervision. For readers the practical message is unchanged. There is no established way to use this compound outside a trial, and nothing in these reports makes buying one safer.

Conclusion

This is a study of text, not of patients. It shows that people taking gray market retatrutide describe a different mix of symptoms than trial participants do, with increased appetite at the top of the list, and it gives other researchers a short list of things to test in data where identity and exposure are known. It cannot show cause, cannot give a rate and cannot confirm what anyone actually injected. Treated as a prompt for further study rather than a finding, it is a reasonable contribution.

Source Sehgal NKR and colleagues. Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide. JAMA Network Open, October 2026. DOI 10.1001/jamanetworkopen.2026.38929

Amino Weekly reports research. It is not medical advice and never gives doses.